KryptoFeed
Business● Neutral 1 min

Galderma Agrees to Acquire ZO Skin Health From Blackstone for $1.5 Billion

Swiss skincare company Galderma has agreed to acquire medical-grade skincare brand ZO Skin Health from investment firm Blackstone for approximately $1.5 billion, Reuters reported on October 13, 2026, citing two people familiar with the transaction. The companies could announce the deal in the coming days. Neither Galderma nor ZO immediately responded to requests for comment, while Blackstone declined to comment.

The acquisition would strengthen Galderma’s position in the U.S. skincare market, where demand for physician-dispensed and clinically backed products continues to attract strategic buyers. Dermatologist Zein Obagi founded ZO Skin Health in 2007. Its products include cleansers, serums, exfoliators, and toners distributed through physicians and skincare professionals. Blackstone acquired a majority stake in the business in 2020 through its Tactical Opportunities fund.

Galderma already owns skincare brands Cetaphil and Alastin Skincare, acne treatment Differin Epiduo, injectable neurotoxin Dysport, and dermal filler Restylane. The company, which dates to 1981, also counts French beauty group L’Oréal as a 20% shareholder. The transaction would expand its portfolio of professional skincare products as companies seek brands with established clinical positioning and consistent consumer demand.

Why it matters

The acquisition highlights growing strategic interest in professional skincare brands and could reshape competition in the medical-grade skincare market. For Blackstone, the transaction would provide an exit from an investment held since 2020.

Priya Raghavan
Personal Finance Writer

Priya explains mutual funds, tax rules, credit and retirement planning for Indian households. A certified financial planner based in Bengaluru, she believes money advice should fit in a single screen.

Up next